Avelox® information for Healthcare Professionals

Avelox® Indications

Avelox® * (moxifloxacin) 400mg film-coated tablets are indicated for the treatment of the following bacterial infections caused by susceptible strains:

  • Community acquired pneumonia (CAP)
  • Acute exacerbations of chronic bronchitis (AECB)
  • Acute bacterial sinusitis (ABS)
  • Mild to Moderate pelvic inflammatory disease (PID)

Avelox® * 400mg intravenous (IV) formulation is indicated for the treatment of the following bacterial infections caused by susceptible strains:

  • Community acquired pneumonia (CAP)
  • Complicated skin and skin structure infections (cSSSI)
  • Complicated intra-abdominal infections (cIAI)

Consideration should be given to official guidance on the appropriate use of antibacterial agents.

Contraindications

Avelox® is contraindicated in the following*:

  • Patients with hypersensitivity to moxifloxacin, other quinolones or to any of the excipients
  • Patients who are pregnant or lactating
  • Patients below 18 years of age

*Contraindications and licensed indications may vary from country to country, please ensure you consult your local prescribing information before prescribing Avelox®.

For further information on using Avelox® in the management of bacterial infections, please consult your local country specific prescribing information.

Avelox® Person - Circles of success